Alzheimer Disease — SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)
Citation(s)
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD): A Multi-center, Randomized, Double-Blind, Placebo-Controlled Safety and Biomarker Study of Pepinemab Anti-SEMA4D Antibody in Early-AD